Nicht aus der Schweiz? Besuchen Sie lehmanns.de

Alcoholic and Non-Alcoholic Fatty Liver Disease (eBook)

Bench to Bedside

Naga Chalasani, Gyongyi Szabo (Herausgeber)

eBook Download: PDF
2015 | 1st ed. 2016
XVI, 372 Seiten
Springer International Publishing (Verlag)
978-3-319-20538-0 (ISBN)

Lese- und Medienproben

Alcoholic and Non-Alcoholic Fatty Liver Disease -
Systemvoraussetzungen
90,94 inkl. MwSt
(CHF 88,85)
Der eBook-Verkauf erfolgt durch die Lehmanns Media GmbH (Berlin) zum Preis in Euro inkl. MwSt.
  • Download sofort lieferbar
  • Zahlungsarten anzeigen

This volume is the first text to concisely yet comprehensively cover developments for both alcoholic and nonalcoholic fatty liver disease in an organized fashion. Aspects of these two diseases covered in the book include global epidemiology and risk factors, pathogenesis, animal models, hepatic and extra-hepatic malignancies, treatment models, and current and emerging therapies.

Written by experts in the field, Alcoholic and Non-Alcoholic Fatty Liver Disease: Bench to Bedside is a valuable resource for gastroenterologists, pathologists, and hepatologists who treat patients with alcoholic and nonalcoholic fatty liver disease.



Drs. Chalasani and Szabo are senior investigators in the field of fatty liver disease and have had extensive federal funding to investigate these areas. They both hold leadership positions and are recognized as experts in the field of fatty liver disease. For example, Dr. Chalasani is the lead author of the multi-society practice guideline on the diagnosis and management of nonalcoholic fatty liver disease& Dr. Szabo is the president-elect of the American Association for the Study of Liver Disease which is the largest liver society in the world. They are also actively practicing clinicians and thus aware of clinically relevant knowledge gaps in the field.

Drs. Chalasani and Szabo are senior investigators in the field of fatty liver disease and have had extensive federal funding to investigate these areas. They both hold leadership positions and are recognized as experts in the field of fatty liver disease. For example, Dr. Chalasani is the lead author of the multi-society practice guideline on the diagnosis and management of nonalcoholic fatty liver disease& Dr. Szabo is the president-elect of the American Association for the Study of Liver Disease which is the largest liver society in the world. They are also actively practicing clinicians and thus aware of clinically relevant knowledge gaps in the field.

1 Epidemiology and Risk Factors for Alcoholic Liver DiseaseMariana Lazo and Mack C. Mitchell2 Global Epidemiology and Risk Factors for Non-Alcoholic Fatty Liver DiseaseAbhijit Chowdhury and Zobair M. Younossi3 Pathogenesis of Alcoholic Liver DiseaseGavin E. Arteel and David W. Crabb4 Pathogenesis of NAFLD and NASHJacquelyn J. Maher5 Animal Models of Alcoholic Liver DiseaseJun Xu and Hidekazu Tsukamoto6 Animal Models of Nonalcoholic Fatty Liver DiseaseMariana Luisa Verdelho Moutinho Machado and Anna Mae Diehl7 Genetic Basis of Alcoholic and Nonalcoholic Fatty Liver DiseaseSilvia Sookoian and Carlos Jose Pirola8 Clinical Features, Disease Modifiers and Natural History of Alcoholic Liver DiseaseLuis S. Marsano, Vatsalya Vatsalya, Ammar Hassan, and Craig J. McClain9 Nonalcoholic Fatty Liver Disease (NAFLD): Clinical Features, Disease Modifiers, and Natural History Dawn M. Torres and Stephen A. Harrison 10 Diagnostic Approaches and Clinical Endpoints of Treatment in Alcoholic Liver DiseaseJaeyoun Cheong, Eva Stein, and Ramon Bataller11 Diagnostic Considerations and Clinical Endpoints for Nonalcoholic SteatohepatitisArun J. Sanyal12 Pathology of Alcoholic and Non-Alcoholic Fatty Liver DiseasePierre Bedossa and David E. Kleiner13 Hepatic and Extra-Hepatic Malignancies in Alcoholic Liver DiseaseSamir Zakhari, Svetlana Radaeva, Vasilis Vasiliou14 Hepatic and Extra-Hepatic Malignancies in NAFLDFabio Nascimbeni and Vlad Ratziu15 Treatment of Alcoholic Liver Disease Including Emerging Therapies, Novel Targets and Liver TransplantationJan Petrasek and Gyongyi Szabo16 Current and Emerging Therapies for Non-Alcoholic Fatty Liver DiseaseSamer Gawrieh and Naga Chalasani17 Nonalcoholic Fatty Liver Disease in ChildrenHannah I. Awai, Kimberly P. Newton, and Jeffrey B. Schwimmer

Erscheint lt. Verlag 10.12.2015
Zusatzinfo XVI, 372 p. 47 illus., 36 illus. in color.
Verlagsort Cham
Sprache englisch
Themenwelt Medizin / Pharmazie Allgemeines / Lexika
Medizin / Pharmazie Medizinische Fachgebiete Innere Medizin
Schlagworte hepatology • Liver histology • liver transplantation • microbiome • NAFLD • Nash
ISBN-10 3-319-20538-2 / 3319205382
ISBN-13 978-3-319-20538-0 / 9783319205380
Haben Sie eine Frage zum Produkt?
PDFPDF (Wasserzeichen)
Größe: 13,0 MB

DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasser­zeichen und ist damit für Sie persona­lisiert. Bei einer missbräuch­lichen Weiter­gabe des eBooks an Dritte ist eine Rück­ver­folgung an die Quelle möglich.

Dateiformat: PDF (Portable Document Format)
Mit einem festen Seiten­layout eignet sich die PDF besonders für Fach­bücher mit Spalten, Tabellen und Abbild­ungen. Eine PDF kann auf fast allen Geräten ange­zeigt werden, ist aber für kleine Displays (Smart­phone, eReader) nur einge­schränkt geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.

Zusätzliches Feature: Online Lesen
Dieses eBook können Sie zusätzlich zum Download auch online im Webbrowser lesen.

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Mehr entdecken
aus dem Bereich